48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
medline:
17
10
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
aheadofprint
Résumé
Buprenorphine extended-release (BUP-XR) provides sustained delivery of buprenorphine to control withdrawal and craving symptoms in the form of a monthly injectable and has been shown to improve health outcomes in patients with opioid use disorder. It is recommended that patients are stabilized with a transmucosal buprenorphine product, for at least 7 days per the product monograph; however, clinically, this timeline may be expedited. We report a case of a hospitalized patient with unregulated fentanyl use who underwent a successful transdermal buprenorphine induction for 48 hours to initiate BUP-XR with minimal levels of withdrawal and without precipitating opioid withdrawal. The approach described could provide a practical, patient-centered, accelerated induction strategy that, once independently validated, could considerably facilitate the use of BUP-XR.
Identifiants
pubmed: 37847573
doi: 10.1097/ADM.0000000000001231
pii: 01271255-990000000-00237
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
Pouya Azar is a consultant on Indivior-led buprenorphine extended-release studies, which are unrelated to this case report. All other authors report no conflicts of interest.
Références
Indivior UK Limited. SUBLOCADE® (buprenorphine extended-release injection) Product Monograph. 2022. https://pdf.hres.ca/dpd_pm/00066524.PDF. Accessed June 5, 2023.
Greenwald MK, Herring AA, Perrone J, et al. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med. 2022;80(6):509–524. doi:https://doi.org/10.1016/j.annemergmed.2022.05.032. Accessed June 5, 2023.
doi: 10.1016/j.annemergmed.2022.05.032
Teruya C, Schwartz RP, Mitchell SG, et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46(5):412–426. doi:10.1080/02791072.2014.921743.
doi: 10.1080/02791072.2014.921743
Schoenfeld EM, Westafer LM, Beck SA, et al. “Just give them a choice”: patients' perspectives on starting medications for opioid use disorder in the ED. Acad Emerg Med. 2022;29(8):928–943.
Hämmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105.
Moe J, O'Sullivan F, Hohl CM, et al. Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114:106740. doi:https://doi.org/10.1016/j.addbeh.2020.106740. Accessed June 5, 2023.
doi: 10.1016/j.addbeh.2020.106740
Ahmed S, Bhivandkar S, Lonergan BB, et al. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30(4):305–315.
Azar P, Wong JSH, Mathew N, et al. 48-Hour induction of transdermal buprenorphine to sublingual buprenorphine/naloxone: The IPPAS method. J Addict Med. 2023;17(2):233–236. doi:10.1097/ADM.0000000000001072.
doi: 10.1097/ADM.0000000000001072
Klaire S, Zivanovic R, Barbic SP, et al. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. Jul 2019;28(4):262–265. doi:10.1111/ajad.12869.
doi: 10.1111/ajad.12869
Priestley T, Chappa AK, Mould DR, et al. Converting from transdermal to buccal formulations of buprenorphine: a pharmacokinetic meta-model simulation in healthy volunteers. Pain Med. 2018;19(10):1988–1996.
Jones AK, Ngaimisi E, Gopalakrishnan M, et al. Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials. Clin Pharmacokinet. 2021;60(4):527–540. doi:10.1007/s40262-020-00957-0.
doi: 10.1007/s40262-020-00957-0
RxODE: Facilities for Simulating from ODE-Based Models. R package version 1.1.5. 2022. https://cran.r-project.org/web/packages/RxODE/index.html. Accessed June 5, 2023.
British Columbia Centre on Substance Use. Risk Mitigation in the Context of Dual Public Health Emergencies — Update to Interim Clinical Guidance. 2022. https://www.bccsu.ca/wp-content/uploads/2022/02/Risk-Mitigation-Guidance-Update-February-2022.pdf. Accessed June 5, 2023.
Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35(2):253–259.
Kahan M, Marion-Bellemare L, Samson J, et al. “Macrodosing” sublingual buprenorphine and extended-release buprenorphine in a hospital setting: 2 case reports. J Addict Med. 2023;17:485–487.
Mariani JJ, Mahony A, Iqbal MN, et al. Case series: Rapid induction onto long acting buprenorphine injection for high potency synthetic opioid users. Am J Addict. 2020;29(4):345–348.
Azar P, Wong JSH, Jassemi S, et al. A case report: rapid Micro-induction of buprenorphine/naloxone to administer buprenorphine extended-release in an adolescent with severe opioid use disorder. Am J Addict. Nov 2020;29(6):531–535. doi:10.1111/ajad.13050.
doi: 10.1111/ajad.13050
DeWeese JP, Krenz JR, Wakeman SE, et al. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: titration, implementation barriers, and strategies to overcomes. Subst Abus. 2021;42(4):506–511. doi:10.1080/08897077.2021.1915914.
doi: 10.1080/08897077.2021.1915914
META:PHI. A Guide to the Use of Depot Buprenorphine. 2022. http://www.metaphi.ca/wp-content/uploads/Guide_DepotBuprenorphine.pdf. Accessed June 5, 2023.
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder. May 23, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder. Accessed June 5, 2023.
Vancouver Coastal Health. High-dose Fentanyl Orders For Withdrawal Management of Patients with Opioid Use Disorder — VGH Pre-Printed Order. http://ppo.vch.ca/vancouver-acute/DocumentsVA/High-dose%20fentanyl%20Orders%20For%20Withdrawal%20Management%20of%20Patients%20with%20Opioid%20Use%20Disorder%20%20VGH%20-%201182%20(Nov%202021).pdf. Accessed June 5, 2023.